www.idosr.org Asha, 2024
©IDOSR PUBLICATIONS
ISSN: 2550-7931

International Digital Organization for Scientific Research
IDOSR JOURNAL OF APPLIED SCIENCES 9(2):63-67, 2024.
https://doi.org/10.59298/IDOSRJAS/2024/9.2.636700
IDOSRJAS9.2.656700

Advances in Targeted Therapy for Cancer: Precision Medicine Approaches

Asha Beatrice Brenda

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Advances in targeted therapy and precision medicine have revolutionized cancer treatment by focusing on therapies that specifically address the molecular and genetic abnormalities driving tumor growth. This review explores the mechanisms underlying targeted therapies, including small molecule inhibitors, monoclonal antibodies, antibody-drug conjugates, and gene editing technologies. The integration of precision medicine, which tailors treatments based on detailed molecular profiling of tumors, has led to significant breakthroughs such as next-generation inhibitors, improved antibody-drug conjugates, and innovative RNA-based therapies. Despite these advances, challenges such as resistance mechanisms, adverse effects, and high costs remain. Future directions include the incorporation of artificial intelligence for drug discovery, expansion of precision oncology, and development of novel therapeutic modalities. A comprehensive literature review and expert consultation to synthesize current advancements and identify future research opportunities was utilised in writing this review article. This article aims to provide insights into how targeted therapy and precision medicine are transforming cancer treatment and outlines the path forward for achieving more effective and personalized cancer care.

Keywords: Targeted Therapy, Precision Medicine, Genomic Profiling, Antibody-Drug Conjugates (ADCs), Artificial Intelligence.

INTRODUCTION

The landscape of cancer treatment has undergone a profound transformation with the advent of targeted therapy and precision medicine. Traditionally, cancer treatments such as chemotherapy and radiation were designed to kill rapidly dividing cells indiscriminately, often leading to significant collateral damage and severe side effects [1–3]. Targeted therapy represents a shift toward more precise interventions that specifically address the molecular and genetic abnormalities driving cancer [4–6]. This approach involves the development of drugs and therapeutic modalities that selectively target cancer-specific pathways, proteins, or genetic mutations, thereby sparing normal cells and reducing adverse effects [7, 8]. Precision medicine further enhances the impact of targeted therapy by tailoring treatments to the individual characteristics of each patient, including their genetic makeup, tumor profile, and overall health status [3, 9]. This personalized approach allows for the identification of the most effective therapies based on detailed molecular diagnostics, improving treatment outcomes and minimizing unnecessary toxicity [10–12]. Recent advancements in genomic sequencing, biomarker identification, and drug development have significantly expanded the scope of targeted therapies, leading to notable successes in treating various cancer types. Innovations such as next-generation tyrosine kinase inhibitors, monoclonal antibodies, and antibody-drug conjugates have demonstrated improved efficacy and specificity [13, 14]. Additionally, the integration of advanced technologies like artificial intelligence and machine learning is accelerating the discovery of new therapeutic targets and optimizing treatment strategies [15, 16]. This review explores the latest developments in targeted therapy within the framework of precision medicine. It examines the underlying mechanisms of targeted therapies, highlights recent breakthroughs and their clinical applications, and addresses the challenges and limitations associated with this approach. By providing a comprehensive overview of current advancements and future directions, this article aims to offer valuable insights into how targeted therapy and precision medicine are reshaping cancer treatment and paving the way for more effective and personalized therapeutic options.

MECHANISMS OF TARGETED THERAPY

Targeted therapies are designed to interfere with specific molecular targets involved in cancer progression. These include:

Small Molecule Inhibitors

Small molecule inhibitors are designed to block the activity of specific proteins involved in cancer cell proliferation and survival. Examples include tyrosine kinase inhibitors (TKIs) like imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia (CML) [5, 17].

Monoclonal Antibodies

Monoclonal antibodies are designed to bind to specific antigens on cancer cells, thereby inhibiting tumor growth or facilitating immune-mediated destruction. Examples include trastuzumab, which targets HER2 in breast cancer [18].

Antibody-Drug Conjugates (ADCs)

ADCs combine the targeting capabilities of monoclonal antibodies with cytotoxic drugs, delivering potent chemotherapy directly to cancer cells. An example is brentuximabvedotin, which targets CD30 in Hodgkin lymphoma [19].

Gene Editing and RNA-Based Therapies

Technologies such as CRISPR/Cas9 and RNA interference are used to modify specific genetic sequences or silence aberrant gene expression, offering potential for personalized cancer treatment [20].

APPLICATIONS OF TARGETED THERAPY IN PRECISION MEDICINE

The application of targeted therapy is increasingly guided by precision medicine principles, which involve tailoring treatments based on detailed molecular profiling of individual tumors.

Genomic Profiling: Genomic profiling involves sequencing the DNA of cancer cells to identify genetic mutations and alterations that drive tumor growth. This information helps in selecting targeted therapies that specifically address these alterations.

Biomarker Identification: Biomarkers are used to predict a patient's response to specific therapies. For instance, the presence of the EGFR mutation in non-small cell lung cancer (NSCLC) guides the use of EGFR inhibitors like erlotinib.

Personalized Treatment Plans: Precision medicine enables the development of individualized treatment plans based on a patient's genetic, molecular, and clinical profile. This approach enhances treatment efficacy and minimizes adverse effects.

Combination Therapies: Combining targeted therapies with other modalities, such as immunotherapy or conventional chemotherapy, can enhance treatment outcomes. For example, combining a BRAF inhibitor with MEK inhibitors has shown improved results in melanoma with BRAF mutations [21-25].

RECENT BREAKTHROUGHS IN TARGETED THERAPY

Recent advancements in targeted therapy have led to significant improvements in cancer treatment. New generation inhibitors with enhanced specificity and reduced resistance profiles are being developed. Examples include second- and third-generation TKIs for NSCLC with EGFR mutations.New ADCs with improved linkers and cytotoxic agents are being developed to enhance therapeutic efficacy and reduce off-target effects. For instance, novel ADCs targeting different tumor antigens are in clinical trials.CRISPR/Cas9 technology is being utilized to target and modify specific genetic mutations in cancer cells, offering potential for precision-based treatments [20, 26]. Clinical trials are exploring its application in various cancers.RNA-based therapies, such as small interfering RNAs (siRNAs) and antisense oligonucleotides, are being developed to target specific oncogenes and reduce tumor growth. These therapies offer a novel approach to personalized cancer treatment [27].

CHALLENGES AND LIMITATIONS

Despite significant progress, several challenges remain in the field of targeted therapy.

Resistance Mechanisms: Cancer cells can develop resistance to targeted therapies through various mechanisms, such as secondary mutations or activation of alternative pathways. Overcoming resistance remains a critical area of research.

Adverse Effects: While targeted therapies are generally more selective than traditional treatments, they can still cause adverse effects, including off-target toxicity and immune reactions. Managing these effects is essential for patient safety.

Accessibility and Cost: The high cost of targeted therapies and the need for specialized testing and facilities pose barriers to widespread access, particularly in low-resource settings.

Evolving Tumor Heterogeneity: Tumors can exhibit significant heterogeneity, with different subclones having distinct molecular profiles. This heterogeneity can complicate treatment strategies and necessitate ongoing monitoring and adaptation [28].

FUTURE DIRECTIONS IN TARGETED THERAPY

The future of targeted therapy is poised to be shaped by several emerging trends.

Integration of Artificial Intelligence: AI and machine learning are being utilized to analyze large datasets, predict treatment responses, and identify new therapeutic targets, potentially accelerating drug discovery and development.

Expansion of Precision Oncology: Continued advancements in genomic and molecular technologies will expand the scope of precision oncology, enabling more precise and effective treatments for a broader range of cancers.

Development of Novel Therapeutic Modalities: Innovative approaches, such as bispecific antibodies and targeted nanomedicines, are being explored to enhance the specificity and efficacy of targeted therapies.

Personalized Combination Strategies: Combining targeted therapies with other treatment modalities, based on individual tumor profiles and patient characteristics, holds promise for achieving more comprehensive and durable responses [29-33].

CONCLUSION

Advances in targeted therapy and precision medicine have significantly transformed cancer treatment, offering more personalized and effective options for patients. While challenges remain, ongoing research and innovation are expected to address these limitations and further enhance the impact of targeted therapies. The future of cancer treatment lies in the continued integration of precision medicine approaches, innovative therapeutic modalities, and advanced technologies, ultimately leading to improved outcomes and quality of life for cancer patients.

REFERENCES

1. Shams, M., Abdallah, S., Alsadoun, L., Hamid, Y.H., Gasim, R., Hassan, A.: Oncological Horizons: The Synergy of Medical and Surgical Innovations in Cancer Treatment. Cureus. 15, e49249. https://doi.org/10.7759/cureus.49249
2. Obeagu, E. I., Omar, D. E., Bunu, U. O., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Leukaemia burden in Africa. *Int. J. Curr. Res. Biol. Med.*, 2023; (1): 17- 22. DOI:10.22192/ijcrbm.2023.08.01.003
3. Obeagu, E.I., Alum, E.U., Obeagu, G.U. and Ugwu, O. P. C. Prostate Cancer: Review on Risk Factors. *Eurasian Experiment Journal of Public Health (EEJPH)*. 2023; 4(1): 4-7.https://www.eejournals.org/public/uploads/1688032824_872978821ba373725554.pdf
4. Røsland, G.V., Engelsen, A.S.T.: Novel Points of Attack for Targeted Cancer Therapy. Basic Clin Pharmacol Toxicol. 116, 9–18 (2015). https://doi.org/10.1111/bcpt.12313
5. Min, H.-Y., Lee, H.-Y.: Molecular targeted therapy for anticancer treatment. Exp Mol Med. 54, 1670–1694 (2022). https://doi.org/10.1038/s12276-022-00864-3
6. Riedl, J.M., Moik, F., Esterl, T., Kostmann, S.M., Gerger, A., Jost, P.J.: Molecular diagnostics tailoring personalized cancer therapy—an oncologist's view. Virchows Arch. 484, 169–179 (2024). https://doi.org/10.1007/s00428-023-03702-7
7. Debela, D.T., Muzazu, S.G., Heraro, K.D., Ndalama, M.T., Mesele, B.W., Haile, D.C., Kitui, S.K., Manyazewal, T.: New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 9, 20503121211034366 (2021). https://doi.org/10.1177/20503121211034366
8. Chehelgerdi, M., Chehelgerdi, M., Allela, O.Q.B., Pecho, R.D.C., Jayasankar, N., Rao, D.P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., Saadh, M.J., Amajd, A., Abo-Zaid, M.A., Castillo-Acobo, R.Y., Ismail, A.H., Amin, A.H., Akhavan-Sigari, R.: Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 22, 169 (2023). https://doi.org/10.1186/s12943-023-01865-0
9. Krzyszczyk, P., Acevedo, A., Davidoff, E.J., Timmins, L.M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J.J., Hartmanshenn, C., O'Neill, K.M., Balter, M.L., Fritz, Z.R., Androulakis, I.P., Schloss, R.S., Yarmush, M.L.: The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 6, 79–100 (2018). https://doi.org/10.1142/S2339547818300020
10. Su, J., Yang, L., Sun, Z., Zhan, X.: Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. Mol Cell Proteomics. 23, 100737 (2024). https://doi.org/10.1016/j.mcpro.2024.100737
11. Stefanicka-Wojtas, D., Kurpas, D.: Personalised Medicine—Implementation to

the Healthcare System in Europe (Focus Group Discussions). J Pers Med. 13, 380 (2023). https://doi.org/10.3390/jpm13030380

12. Alowais, S.A., Alghamdi, S.S., Alsuhebany, N., Alqahtani, T., Alshaya, A.I., Almohareb, S.N., Aldairem, A., Alrashed, M., Bin Saleh, K., Badreldin, H.A., Al Yami, M.S., Al Harbi, S., Albekairy, A.M.: Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education. 23, 689 (2023). https://doi.org/10.1186/s12909-023-04698-z
13. Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., Zang, Y.-S.: New clinical trial design in precision medicine: discovery, development and direction. Sig Transduct Target Ther. 9, 1–29 (2024). https://doi.org/10.1038/s41392-024-01760-0
14. Liu, B., Zhou, H., Tan, L., Siu, K.T.H., Guan, X.-Y.: Exploring treatment options in cancer: Tumor treatment strategies. Sig Transduct Target Ther. 9, 1–44 (2024). https://doi.org/10.1038/s41392-024-01856-7
15. Yadav, S., Singh, A., Singhal, R., Yadav, J.P.: Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. Intelligent Pharmacy. 2, 367–380 (2024). https://doi.org/10.1016/j.ipha.2024.02.009
16. Visan, A.I., Negut, I.: Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life (Basel). 14, 233 (2024). https://doi.org/10.3390/life14020233
17. Liu, G.-H., Chen, T., Zhang, X., Ma, X.-L., Shi, H.-S.: Small molecule inhibitors targeting the cancers. MedComm. 3, (2022). https://doi.org/10.1002/mco2.181
18. Zahavi, D., Weiner, L.: Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 9, 34 (2020). https://doi.org/10.3390/antib9030034
19. Wang, Z., Li, H., Gou, L., Li, W., Wang, Y.: Antibody–drug conjugates: Recent advances in payloads. Acta Pharm Sin B. 13, 4025–4059 (2023). https://doi.org/10.1016/j.apsb.2023.06.015
20. Rabaan, A.A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M.A., Nassar, M.S., Alsaleh, A.A., Alhashem, Y.N., Bukhamseen, A.Y., Al-Ruhimy, K., Alotaibi, M., Alsubki, R.A., Alahmed, H.E., Al-Abdulhadi, S., Alhashem, F.A., Alqatari, A.A., Alsayyah, A., Farahat, R.A., Abdulal, R.H., Al-Ahmed, A.H., Imran, Mohd., Mohapatra, R.K.: Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction. Curr Oncol. 30, 1954–1976 (2023). https://doi.org/10.3390/curroncol30020152
21. Berger, M.F., Mardis, E.R.: The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 15, 353–365 (2018). https://doi.org/10.1038/s41571-018-0002-6
22. Malone, E.R., Oliva, M., Sabatini, P.J.B., Stockley, T.L., Siu, L.L.: Molecular profiling for precision cancer therapies. Genome Med. 12, 8 (2020). https://doi.org/10.1186/s13073-019-0703-1
23 Alum, E. U.**,**Obeagu, E. I., Ugwu, O. P. C., Orji, O. U., Adepoju, A. O., Amusa, M. O. Edwin, N.Exploring natural plant products in breast cancer management: A comprehensive review and future prospects**.***International Journal of Innovative and Applied Research.* 2023; 11(12):1-9.Article DOI:10.58538/IJIAR/2055. DOI URL:*http://dx.doi.org/10.58538/IJIAR/2055*
24 Alum, E. U., Ugwu, O. P. C., Obeagu, E. I.Cervical Cancer Prevention Paradox: Unveiling Screening Barriers and Solutions, *J, Cancer Research and Cellular Therapeutics. 2024*, 8(2):1-5. DOI:10.31579/2640-1053/182
25 Alum, E. U., Ugwu, O. P. C., Obeagu, E. I.,Ugwu, C. N.Beyond Conventional Therapies: Exploring Nutritional Interventions for Cervical Cancer Patients, *J, Cancer Research and Cellular Therapeutics*, 8(1);1-6. DOI:10.31579/2640-1053/180
26. Attili, I., Corvaja, C., Spitaleri, G., Del Signore, E., Trillo Aliaga, P., Passaro, A., de Marinis, F.: New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations. Cancers (Basel). 15, 5079 (2023). https://doi.org/10.3390/cancers15205079
27. Saw, P.E., Song, E.: Advancements in clinical RNA therapeutics: Present developments and prospective outlooks. Cell Rep Med. 5, 101555 (2024). https://doi.org/10.1016/j.xcrm.2024.101555
28. Lei, Z.-N., Tian, Q., Teng, Q.-X., Wurpel, J.N.D., Zeng, L., Pan, Y., Chen, Z.-S.: Understanding and targeting resistance mechanisms in cancer. MedComm. 4, (2023). https://doi.org/10.1002/mco2.265
29 Ugwu OPC, Anyanwu CN, Alum EU, Okon MB, Egba SI, Uti DE and Awafung EA. (2024).CRISPR-Cas9 Mediated Gene Editing for Targeted Cancer Therapy: Mechanisms,

Challenges, and Clinical Applications. Newport International Journal Of Biological And AppliedSciences,5(1):97-102. https://doi.org/10.59298/NIJBAS/2024/5.1.9297102

30 Obeagu, E.I., Alum, E.U.,Obeagu, G.U. and Ugwu, O. P. C. Benign Prostatic Hyperplasia: A Review. *Eurasian Experiment Journal of Public Health (EEJPH).* 2023; 4(1): 1-3.https://www.eejournals.org/public/uploads/1687980288_52785ca83cc0c789d8ae.pdf

31 Ibiam, U. A., Uti, D. E., Ejeogo, C. C., Orji, O. U., Aja, P. M., Ezeaani, N. N., Alum, E. U.,Chukwu, C., AlokeC., Chinedum, K. E., Agu, P. and Nwobodo, V.In Vivo and in Silico Assessment of Ameliorative Effects of Xylopiaaethiopica on Testosterone Propionate-Induced Benign Prostatic Hyperplasia.*Pharmaceut Fronts.* 2023;5: e64–e76.DOI:10.1055/s-0043-1768477

32 Alum, E. U., Inya, J. E., Ugwu, O. P. C., Obeagu, I.E., Aloke, C., Aja, P. M., Okpata, M. G., John, E. C., Orji, M. O. and Onyema, O. Ethanolic leaf extract of *Daturastramonium* attenuates Methotrexate-induced Biochemical Alterations in Wistar Albino rats. *RPSPharmacy and Pharmacology Reports*, 2023; 2(1):1–6. doi: 10.1093/rpsppr/rqac011.

33 Aja, P. M., Agu, P. C., Ezeh, E. M., Awoke, J. N., Ogwoni, H. A., Deusdedit, T., Ekpono, E. U., Igwenyi, I. O., Alum, E. U., Ugwuja, E. I., Ibiam, U. A., Afiukwa, C. A. and Adegboyega, A. E. Prospect into therapeutic potentials of Moringa oleifera phytocompounds against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies. *Bulletin of the National Research Centre.* 2021;45(1):1-18. https://doi.org/10.1186/s42269-021-00554-6

CITE AS: Asha Beatrice Brenda (2024). Advances in Targeted Therapy for Cancer: Precision Medicine Approaches. IDOSR JOURNAL OF APPLIED SCIENCES 9(2):63-67. https://doi.org/10.59298/IDOSRJAS/2024/9.2.636700